Strategic Capital Syncona’s long-term, strategic capital base and significant ownership in portfolio companies create recurring outbound opportunities for collaboration, co-investment, or consultancy services with a focus on scale and commercialisation of life sciences assets.

Portfolio Growth With a vision to build 20-25 companies across innovative healthcare areas, there is potential to pitch deal flow services, venture scouting partnerships, and targeted introductions to high-potential biotech founders and management teams.

Recent Ventures Active investments and exits, such as Seed funding for Re-Aim Therapeutics and collaborations like iOnctura, indicate openness to partnering on early-stage financing, strategic advisory, and technology licensing opportunities.

Leadership & Network Key personnel changes and the addition of independent directors suggest opportunities for executive search, board advisory, and governance services to support scaling portfolio companies.

Strategic Divestments Past asset disposals to big pharma demonstrate a landscape where selling or licensing assets to large incumbents can be a viable exit path; potential to present partnerships on asset monetization and opportunistic licensing deals.